IP Library Granted Patent US 7,300,919
Granted Patent B2
US 7,300,919 · App. 10/245,707 · Granted Nov 27, 2007

Pulmonary delivery of active fragments of parathyroid hormone

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,300,919
App. No.
10/245,707
Granted
Nov 27, 2007
Kind
B2
Abstract

Systemic delivery of parathyroid hormone to a mammalian host is accomplished by inhalation through the mouth of a dispersion of an N-terminal fragment of PTH. It has been found that such respiratory delivery of the PTH fragment provides a pulsatile concentration profile of the PTH in the host's serum. PTH fragment compositions include dry powder formulations having the PTH present in a dry bulking powder, liquid solutions or suspensions suitable for nebulization, and aerosol propellants suitable for use in a metered dose inhaler.

Claims (6)

1. A therapeutic composition in solid dose form comprising a bulking agent and an N-terminal peptide fragment of parathyroid hormone (PTH) as a bioactive agent, wherein said composition is a powder suitable for administration by inhalation, said bulking agent is selected from the group consisting of sucrose, lactose, trehalose, dextran and maltotriose, and said powder has a particle size between 0.5 μm to 5 μm.

2. The composition according to claim 1 , wherein said peptide fragment consists of the first 34 amino acids of SEQ ID NO: 1.

3. The composition according to claim 1 , wherein said peptide fragment consists of the first 34 to 38 amino acids of SEQ ID NO: 1.

4. The composition according to claim 1 , further comprising an additive to maintain or enhance chemical stability and physiological acceptability.

5. The composition according to claim 4 , wherein the additive is a peptidase inhibitor.

6. The composition according to claim 4 , wherein the additive is a chelating agent.

Assignments (1)
ASSIGNMENT OF PATENT RIGHTS Recorded Jan 7, 2009
From: NEKTAR THERAPEUTICS
To: NOVARTIS PHARMA AG
Reel/Frame 022071/0001 →